{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:58:39Z","timestamp":1784869119206,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI P30 CA016672"],"award-info":[{"award-number":["NCI P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The validation of the Treatment-induced Neuropathy Assessment Scale (TNAS v2.0), a patient-reported outcome measure of symptoms associated with cancer treatment-induced peripheral neuropathy (TIPN), was previously reported. Further patient input (qualitative interviewing, cognitive debriefing) suggested that the measure should be modified to better reflect the TIPN experience. We report the performance of a revised version (TNAS v3.0) for assessing TIPN across cancer treatments. This TNAS version incorporates extensive patient input, in accordance with FDA guidance on the development of patient-reported outcomes measures. Patients with multiple myeloma, colorectal cancer, or gynecological cancer treated with bortezomib, oxaliplatin, or taxane\u2013platinum combination therapy, respectively, completed the TNAS v3.0, European Organization for Research and Treatment of Cancer Chemotherapy-Induced Peripheral Neuropathy (EORTC-CIPN20), and a cognitive debriefing survey during a scheduled clinic visit. Patients also participated in in-depth qualitative interviews about their TIPN symptoms. The psychometric properties of the TNAS v3.0 were evaluated.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Cognitive debriefing survey results were summarized and showed that most patients found the items easy to complete, comprehensible, acceptable, and not redundant. A notable change from TNAS v2.0 was the separation of \u201cnumbness\u201d from \u201ctingling,\u201d although these 2 items remained the most severe, followed by a new \u201cpain\u201d item. The Cronbach coefficient alphas for the 9-item TNAS were 0.88 and 0.90 at the first and second administrations, respectively, indicating good reliability. The test\u2013retest reliability of the TNAS was 0.97. The correlation coefficients for the 9-item TNAS and the EORTC-CIPN20 were 0.69 for the sensory subscale, 0.70 for the motor subscale, and 0.32 for the autonomic subscale, indicating good validity.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This psychometric evaluation showed that the TNAS v3.0 is valid and reliable. Further research is needed to determine clinically meaningful differences in TNAS v3.0 scores and demonstrate its responsiveness over time.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s41687-020-0180-8","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T14:03:14Z","timestamp":1602684194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment"],"prefix":"10.1186","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-5233","authenticated-orcid":false,"given":"Tito R.","family":"Mendoza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2348-8005","authenticated-orcid":false,"given":"Xin Shelley","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwatosin","family":"Bamidele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanie F.","family":"Woodruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1460-6527","authenticated-orcid":false,"given":"Charles S.","family":"Cleeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,19]]},"reference":[{"key":"180_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","volume":"32","author":"DL Hershman","year":"2014","unstructured":"Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., Chauhan, C., Gavin, P., Lavino, A., Lustberg, M. B., Paice, J., Schneider, B., Smith, M. L., Smith, T., Terstriep, S., Wagner-Johnston, N., Bak, K., & Loprinzi, C. L. (2014). American Society of Clinical O: Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 32, 1941\u20131967.","journal-title":"J Clin Oncol"},{"key":"180_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","volume":"63","author":"SB Park","year":"2013","unstructured":"Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013). Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA Cancer J Clin, 63, 419\u2013437.","journal-title":"CA Cancer J Clin"},{"key":"180_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/CMAR.S44261","volume":"6","author":"AA Argyriou","year":"2014","unstructured":"Argyriou, A. A., Kyritsis, A. P., Makatsoris, T., & Kalofonos, H. P. (2014). Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature. Cancer Manag Res, 6, 135\u2013147.","journal-title":"Cancer Manag Res"},{"key":"180_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/jns5.12073","volume":"19","author":"G Cavaletti","year":"2014","unstructured":"Cavaletti, G. (2014). Chemotherapy-induced peripheral neurotoxicity (CIPN): What we need and what we know. J Peripher Nerv Syst, 19, 66\u201376.","journal-title":"J Peripher Nerv Syst"},{"key":"180_CR5","first-page":"599","volume":"7","author":"E Esin","year":"2014","unstructured":"Esin, E., & Yalcin, S. (2014). Neuropathic cancer pain: What we are dealing with? How to manage it? Onco Targets Ther, 7, 599\u2013618.","journal-title":"Onco Targets Ther"},{"key":"180_CR6","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","volume":"31","author":"F Mols","year":"2013","unstructured":"Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., & van de Poll-Franse, L. V. (2013). Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: Results from the population-based PROFILES registry. J Clin Oncol, 31, 2699\u20132707.","journal-title":"J Clin Oncol"},{"key":"180_CR7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/mus.25264","volume":"55","author":"JS Gewandter","year":"2017","unstructured":"Gewandter, J. S., Burke, L., Cavaletti, G., Dworkin, R. H., Gibbons, C., Gover, T. D., Herrmann, D. N., McArthur, J. C., McDermott, M. P., Rappaport, B. A., Reeve, B. B., Russell, J. W., Smith, A. G., Smith, S. M., Turk, D. C., Vinik, A. I., & Freeman, R. (2017). Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy. Muscle Nerve, 55, 366\u2013372.","journal-title":"Muscle Nerve"},{"key":"180_CR8","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jpain.2015.07.002","volume":"16","author":"TR Mendoza","year":"2015","unstructured":"Mendoza, T. R., Wang, X. S., Williams, L. A., Shi, Q., Vichaya, E. G., Dougherty, P. M., Thomas, S. K., Yucel, E., Bastida, C. C., Woodruff, J. F., & Cleeland, C. S. (2015). Measuring therapy-induced peripheral neuropathy: Preliminary development and validation of the treatment-induced neuropathy assessment scale. J Pain, 16, 1032\u20131043.","journal-title":"J Pain"},{"key":"180_CR9","first-page":"268","volume-title":"Cancer symptom science: Measurement, mechanisms, and management","author":"CS Cleeland","year":"2011","unstructured":"Cleeland, C. S., & Mendoza, T. R. (2011). Symptom measurement by patient report. In C. S. Cleeland, M. J. Fisch, & A. J. Dunn (Eds.), Cancer symptom science: Measurement, mechanisms, and management (pp. 268\u2013284). Cambridge: Cambridge University Press."},{"key":"180_CR10","unstructured":"US Department of Health and Human Services Food and Drug Administration: Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf. Accessed 19 Mar 2018."},{"key":"180_CR11","unstructured":"Williams, L. A., Garcia-Gonzalez, A., Mendoza, T. R., Haq, S., & Cleeland, C. S. (2018). Concept domain validation and item generation for the treatment-induced neuropathy assessment scale (TNAS). Support Care Cancer [Epub ahead of print]."},{"key":"180_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1037\/0003-066X.34.7.571","volume":"34","author":"RM Dawes","year":"1979","unstructured":"Dawes, R. M. (1979). The robust beauty of improper linear models in decision making. Am Psychol, 34, 571\u2013582.","journal-title":"Am Psychol"},{"key":"180_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2307\/2982889","volume":"155","author":"DR Cox","year":"1992","unstructured":"Cox, D. R., Fitzpatrick, R., Fletcher, A. E., Gore, S. M., Spiegelhalter, D. J., & Jones, D. R. (1992). Quality-of-life assessment: Can we keep it simple? J Roy Stat Soc a Sta, 155, 353\u2013393.","journal-title":"J Roy Stat Soc a Sta"},{"key":"180_CR14","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","volume":"22","author":"EM Lavoie Smith","year":"2013","unstructured":"Lavoie Smith, E. M., Barton, D. L., Qin, R., Steen, P. D., Aaronson, N. K., & Loprinzi, C. L. (2013). Assessing patient-reported peripheral neuropathy: The reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 questionnaire. Qual Life Res, 22, 2787\u20132799.","journal-title":"Qual Life Res"},{"key":"180_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","volume":"41","author":"TJ Postma","year":"2005","unstructured":"Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., Hoang-Xuan, K., Lanteri-Minet, M., Grant, R., Huddart, R., Moynihan, C., Maher, J., Lucey, R., & Group EQoL. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer, 41, 1135\u20131139.","journal-title":"Eur J Cancer"},{"key":"180_CR16","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1200\/JCO.2010.33.0308","volume":"29","author":"CL Loprinzi","year":"2011","unstructured":"Loprinzi, C. L., Reeves, B. N., Dakhil, S. R., Sloan, J. A., Wolf, S. L., Burger, K. N., Kamal, A., Le-Lindqwister, N. A., Soori, G. S., Jaslowski, A. J., Novotny, P. J., & Lachance, D. H. (2011). Natural history of paclitaxel-associated acute pain syndrome: Prospective cohort study NCCTG N08C1. J Clin Oncol, 29, 1472\u20131478.","journal-title":"J Clin Oncol"},{"key":"180_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00520-011-1141-9","volume":"20","author":"SL Wolf","year":"2012","unstructured":"Wolf, S. L., Barton, D. L., Qin, R., Wos, E. J., Sloan, J. A., Liu, H., Aaronson, N. K., Satele, D. V., Mattar, B. I., Green, N. B., & Loprinzi, C. L. (2012). The relationship between numbness, tingling, and shooting\/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer, 20, 625\u2013632.","journal-title":"Support Care Cancer"},{"key":"180_CR18","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., Molsen, E., & Ring, L. (2011). Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 2--assessing respondent understanding. Value Health, 14, 978\u2013988.","journal-title":"Value Health"},{"key":"180_CR19","doi-asserted-by":"publisher","DOI":"10.4135\/9781412983655","volume-title":"Cognitive interviewing: A tool for improving questionnaire design","author":"GB Willis","year":"2005","unstructured":"Willis, G. B. (2005). Cognitive interviewing: A tool for improving questionnaire design. Thousand Oaks: SAGE Publications, Inc.."},{"key":"180_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2165\/00019053-200826050-00002","volume":"26","author":"NK Leidy","year":"2008","unstructured":"Leidy, N. K., & Vernon, M. (2008). Perspectives on patient-reported outcomes : Content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics, 26, 363\u2013370.","journal-title":"Pharmacoeconomics"},{"key":"180_CR21","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale: L. Erlbaum Associates.","edition":"2"},{"key":"180_CR22","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","volume":"89","author":"CS Cleeland","year":"2000","unstructured":"Cleeland, C. S., Mendoza, T. R., Wang, X. S., Chou, C., Harle, M. T., Morrissey, M., & Engstrom, M. C. (2000). Assessing symptom distress in cancer patients: The M.D. Anderson symptom inventory. Cancer, 89, 1634\u20131646.","journal-title":"Cancer"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-020-0180-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s41687-020-0180-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-020-0180-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T08:40:22Z","timestamp":1613637622000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-020-0180-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,19]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["180"],"URL":"https:\/\/doi.org\/10.1186\/s41687-020-0180-8","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,19]]},"assertion":[{"value":"9 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients gave informed consent to participate in the study, which was approved by our Institutional Review Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}